A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection
Recruiting · NCT06746883
Conditions: Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
At a glance
- Research payments reported, 2025
- $158,795
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 100
About the trial
- Sponsor
- Innoviva Specialty Therapeutics
- Tested
- Non-interventional (other)
- Dates
- Started 2025-04-28; completion 2029-01-31
- Results posted
- Not yet
The goal of this observational study is to evaluate the safety of sulbactam-durlobactam, as well as the risk of hypersensitivity reactions (including anaphylaxis) in participants with Acinetobacter baumannii-calcoaceticus complex infection. Participants will be followed for approximately 28 days in order to collect safety and reaction data.
From ClinicalTrials.gov, last updated 2026-06-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
La Jolla Pharmaceutical Company reported $158,795 in research payments for this study in 2025 (24 payments).
Products named: Xacduro
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Lisa A. Clough, M.D. Infectious Disease · Kansas City, KS
- Jonathan M. Hand, M.D. Infectious Disease · New Orleans, LA
- Paul Riska, MD Infectious Disease · Bronx, NY
- John M. Cafardi, M.D. Infectious Disease · Cincinnati, OH
- Michael J. Tan, MD Infectious Disease · Akron, OH
- Amanda E. Schnee, MD Infectious Disease · Greenville, SC
- Alexandre E. Malek, MD Infectious Disease · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Lsu Health Sciences Center $45,606
- Biomedical Research Alliance of New York LLC $30,760
- Summa Health $21,758
- Ochsner Medical Center Acute, LA $17,369
- Kumc Research Institute Inc $17,102
- The Carl and Edyth Lindner $13,200
- Prisma Health Hillcrest Hospital, SC $13,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.